Celadon Pharmaceuticals Regulatory News (CEL)

26 Jul 2006 07:01

Celsis International PLC26 July 2006 CELSIS INTERNATIONAL PLC AGM STATEMENT 26 July 2006: Celsis International plc, the life sciences products and servicescompany, will today hold its Annual General Meeting. Dr Jack Rowell, NonExecutive Chairman of Celsis, will make the following comments: "In the year ended 31 March 2006, Celsis delivered another strong set offinancial results, reporting double digit organic profit growth and asubstantial increase in revenues. The current financial year has started welland I can report that the integration of In Vitro Technologies (IVT) isprogressing well following completion of the acquisition. "The acquisition of IVT provides attractive growth prospects in the in-vitroADME-Tox market and brings new skills and expertise to the Group. We expect IVTto significantly transform the Group by providing an increased product andservices portfolio, as well as creating strong cross-selling opportunities inthe pharmaceutical and biopharmaceutical industries. "Our Rapid Diagnostics business, which provides rapid detection systems enablingfast quality control of products bound for consumers, has continued its strongorganic growth as customers increasingly adopt our rapid microbial testingsystems. We continue to invest in R&D to ensure that Celsis remains at theforefront of rapid detection systems. This division continues to make goodprogress during the first half of this year. "Our Laboratory Group saw a strong performance in the second half of last yearwith increased orders from our growing pharmaceutical and biopharmaceuticalcustomer base. We are pleased to report that we continue to experience growthin this division." Enquiries: Celsis International plc Tel: 01638 600 151Jay LeCoque, Chief Executive OfficerJenny Parsons, Corporate Communications Financial Dynamics Tel: 020 7831 3113Ben AtwellAnna Keeble Notes to editors Celsis International plc Celsis International plc provides value enhancing products and services to thepharmaceutical, biopharmaceutical, personal care and beverage industries throughits three business areas; rapid detection systems, analytical services and invitro technologies. The company is listed on the London Stock Exchange (CEL.L). Using proprietary technology, the rapid detection business is the world leaderin the provision of diagnostic systems for the rapid detection of contamination.It works in close collaboration with many of the world's leadingpharmaceutical, personal care and beverage companies, ensuring the safety andquality of products bound for consumers. The Laboratory Group providesoutsourced analytical testing services to pharmaceutical and biopharmaceuticalcompanies to ensure the stability and chemical composition of their products.In Vitro Technologies (IVT) supplies in vitro testing products and services tothe pharmaceutical and biotechnology industries to improve the drug discoveryand development process and reduce its cost. In addition to ensuring product quality and safety for consumers, each divisionhas the capacity to deliver substantial cost savings to Celsis' customers. Byreducing the time it takes to test and release raw materials and finished goodsto the market place, Celsis' products facilitate increased manufacturingproductivity and improved supply chain management. IVT's drug testing productsand services cut the time and cost of drug discovery and development, as anestimated 50% of drug compounds fail during early stage development due to ADME(Absorption, Distribution, Metabolism and Excretion) or toxicity. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange